CASI Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

CASI Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 9% bzw. 35.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 12.9% pro Jahr wachsen soll.

Wichtige Informationen

9.0%

Wachstumsrate der Gewinne

12.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	35.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25

Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Mar 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CASI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	70	-28	N/A	N/A	1
12/31/2025	46	-33	N/A	N/A	1
12/31/2024	20	-36	N/A	N/A	1
9/30/2024	22	-31	N/A	N/A	N/A
6/30/2024	23	-27	N/A	N/A	N/A
3/31/2024	29	-30	N/A	N/A	N/A
12/31/2023	34	-27	-22	-20	N/A
9/30/2023	42	-40	N/A	N/A	N/A
6/30/2023	44	-41	N/A	N/A	N/A
3/31/2023	42	-38	N/A	N/A	N/A
12/31/2022	43	-41	-27	-21	N/A
9/30/2022	37	-27	-35	-28	N/A
6/30/2022	35	-32	-35	-25	N/A
3/31/2022	33	-31	-34	-23	N/A
12/31/2021	30	-37	-42	-27	N/A
9/30/2021	26	-45	-44	-27	N/A
6/30/2021	22	-52	-54	-30	N/A
3/31/2021	17	-54	-53	-29	N/A
12/31/2020	15	-48	-43	-26	N/A
9/30/2020	12	-47	-41	-23	N/A
6/30/2020	10	-40	-29	-21	N/A
3/31/2020	8	-46	-36	-23	N/A
12/31/2019	4	-46	-37	-23	N/A
9/30/2019	3	-43	-42	-34	N/A
6/30/2019	N/A	-42	-42	-33	N/A
3/31/2019	N/A	-32	-31	-28	N/A
12/31/2018	N/A	-27	-50	-29	N/A
9/30/2018	N/A	-23	-35	-15	N/A
6/30/2018	N/A	-16	N/A	-12	N/A
3/31/2018	N/A	-13	N/A	-11	N/A
12/31/2017	N/A	-11	N/A	-6	N/A
9/30/2017	N/A	-8	N/A	-7	N/A
6/30/2017	N/A	-8	N/A	-7	N/A
3/31/2017	N/A	-9	N/A	-6	N/A
12/31/2016	N/A	-9	N/A	-6	N/A
9/30/2016	N/A	-8	N/A	-6	N/A
6/30/2016	N/A	-8	N/A	-6	N/A
3/31/2016	0	-7	N/A	-6	N/A
12/31/2015	0	-7	N/A	-6	N/A
9/30/2015	0	-7	N/A	-5	N/A
6/30/2015	0	-27	N/A	-5	N/A
3/31/2015	0	-27	N/A	-4	N/A
12/31/2014	0	-26	N/A	-4	N/A
9/30/2014	N/A	-26	N/A	-4	N/A
6/30/2014	N/A	-6	N/A	-4	N/A
3/31/2014	N/A	-6	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CASI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CASI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CASI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CASIDie Einnahmen des Unternehmens (35.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: CASIDie Einnahmen des Unternehmens (35.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CASI in 3 Jahren voraussichtlich hoch sein wird

CASI Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 67%

No longer forecast to breakeven

Forecast to breakeven in 2024

Consensus EPS estimates upgraded to US$1.88 loss, revenue downgraded

Consensus forecasts updated

Forecast to breakeven in 2024

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals, Inc. Announces Change of Senior Management Positions

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO

CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd.

CASI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Consensus revenue estimates fall by 67%

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

First quarter 2024 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug (IND) Application for CID-103 in Immune Thrombocytopenia

New minor risk - Profitability

CASI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China

CASI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 20, 2024

Casi Pharmaceuticals Announces First Dose of Folotyn in China

CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer

CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2024

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CASI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CASI Pharmaceuticals, Inc.(NasdaqCM:CASI) dropped from S&P TMI Index

Consensus EPS estimates upgraded to US$1.88 loss, revenue downgraded

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

CASI Pharmaceuticals, Inc. Announces Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China

Consensus forecasts updated

Forecast to breakeven in 2024

Price target decreased to US$18.33

Insufficient new directors

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

Consensus forecasts updated

Price target decreased to US$22.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CASI Pharmaceuticals Q2 2022 Earnings Preview

CASI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Chairman & CEO recently bought US$273k worth of stock

Price target decreased to US$37.00

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

No longer forecast to breakeven

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

CASI Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to US$4.67

Insufficient new directors

CASI Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Price target increased to US$4.67

CASI Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice

Forecast to breakeven in 2024

CASI Pharmaceuticals, Inc. (NasdaqCM:CASI) announces an Equity Buyback for $10 million worth of its shares.

Casi Pharmaceuticals and Bioinvent Announce CTA Approval for Clinical Study of Bi-1206 in NHL in China

Chairman & CEO recently bought US$394k worth of stock

Third quarter 2021 earnings released: US$0.073 loss per share (vs US$0.14 loss in 3Q 2020)

Chairman & CEO recently bought US$614k worth of stock

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.086 loss in 2Q 2020)

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Price target increased to US$4.45

Consensus revenue estimates increase to US$28.5m